These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 23425074)

  • 1. CXCR2: a target for pancreatic cancer treatment?
    Hertzer KM; Donald GW; Hines OJ
    Expert Opin Ther Targets; 2013 Jun; 17(6):667-80. PubMed ID: 23425074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duffy antigen receptor for chemokines (DARC) expressing in cancer cells inhibits tumor progression by suppressing CXCR2 signaling in human pancreatic ductal adenocarcinoma.
    Maeda S; Kuboki S; Nojima H; Shimizu H; Yoshitomi H; Furukawa K; Miyazaki M; Ohtsuka M
    Cytokine; 2017 Jul; 95():12-21. PubMed ID: 28214673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCR2 signaling promotes secretory cancer-associated fibroblasts in pancreatic ductal adenocarcinoma.
    Awaji M; Saxena S; Wu L; Prajapati DR; Purohit A; Varney ML; Kumar S; Rachagani S; Ly QP; Jain M; Batra SK; Singh RK
    FASEB J; 2020 Jul; 34(7):9405-9418. PubMed ID: 32453916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer.
    Purohit A; Varney M; Rachagani S; Ouellette MM; Batra SK; Singh RK
    Oncotarget; 2016 Feb; 7(6):7280-96. PubMed ID: 26771140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting IL-8 in colorectal cancer.
    Ning Y; Lenz HJ
    Expert Opin Ther Targets; 2012 May; 16(5):491-7. PubMed ID: 22494524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma.
    Chao T; Furth EE; Vonderheide RH
    Cancer Immunol Res; 2016 Nov; 4(11):968-982. PubMed ID: 27737879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseases.
    Cheng Y; Ma XL; Wei YQ; Wei XW
    Biochim Biophys Acta Rev Cancer; 2019 Apr; 1871(2):289-312. PubMed ID: 30703432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crystallographic analysis of NHERF1-PLCβ3 interaction provides structural basis for CXCR2 signaling in pancreatic cancer.
    Jiang Y; Wang S; Holcomb J; Trescott L; Guan X; Hou Y; Brunzelle J; Sirinupong N; Li C; Yang Z
    Biochem Biophys Res Commun; 2014 Apr; 446(2):638-43. PubMed ID: 24642259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer.
    Zhang M; Huang L; Ding G; Huang H; Cao G; Sun X; Lou N; Wei Q; Shen T; Xu X; Cao L; Yan Q
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32051287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting CXCR2 enhances chemotherapeutic response, inhibits mammary tumor growth, angiogenesis, and lung metastasis.
    Sharma B; Nawandar DM; Nannuru KC; Varney ML; Singh RK
    Mol Cancer Ther; 2013 May; 12(5):799-808. PubMed ID: 23468530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human pituitary tumor-transforming gene 1 overexpression reinforces oncogene-induced senescence through CXCR2/p21 signaling in breast cancer cells.
    Ruan JW; Liao YC; Lua I; Li MH; Hsu CY; Chen JH
    Breast Cancer Res; 2012 Jul; 14(4):R106. PubMed ID: 22789011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CXCR2: A Novel Mediator of Mammary Tumor Bone Metastasis.
    Sharma B; Nannuru KC; Saxena S; Varney ML; Singh RK
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30871004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of CXCR2 ligands, stem cell-like phenotype, and metastasis in chemotherapy-resistant breast cancer cells.
    Sharma B; Varney ML; Saxena S; Wu L; Singh RK
    Cancer Lett; 2016 Mar; 372(2):192-200. PubMed ID: 26797460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
    Devapatla B; Sharma A; Woo S
    PLoS One; 2015; 10(9):e0139237. PubMed ID: 26414070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting both tumour-associated CXCR2
    Nywening TM; Belt BA; Cullinan DR; Panni RZ; Han BJ; Sanford DE; Jacobs RC; Ye J; Patel AA; Gillanders WE; Fields RC; DeNardo DG; Hawkins WG; Goedegebuure P; Linehan DC
    Gut; 2018 Jun; 67(6):1112-1123. PubMed ID: 29196437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer.
    Matsuo Y; Raimondo M; Woodward TA; Wallace MB; Gill KR; Tong Z; Burdick MD; Yang Z; Strieter RM; Hoffman RM; Guha S
    Int J Cancer; 2009 Sep; 125(5):1027-37. PubMed ID: 19431209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells.
    Schinke C; Giricz O; Li W; Shastri A; Gordon S; Barreyro L; Bhagat T; Bhattacharyya S; Ramachandra N; Bartenstein M; Pellagatti A; Boultwood J; Wickrema A; Yu Y; Will B; Wei S; Steidl U; Verma A
    Blood; 2015 May; 125(20):3144-52. PubMed ID: 25810490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-17-CXC Chemokine Receptor 2 Axis Facilitates Breast Cancer Progression by Up-Regulating Neutrophil Recruitment.
    Wu L; Awaji M; Saxena S; Varney ML; Sharma B; Singh RK
    Am J Pathol; 2020 Jan; 190(1):222-233. PubMed ID: 31654638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GRO-α and IL-8 enhance ovarian cancer metastatic potential via the CXCR2-mediated TAK1/NFκB signaling cascade.
    Yung MM; Tang HW; Cai PC; Leung TH; Ngu SF; Chan KK; Xu D; Yang H; Ngan HY; Chan DW
    Theranostics; 2018; 8(5):1270-1285. PubMed ID: 29507619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCR2 and RET single nucleotide polymorphisms in pancreatic cancer.
    Donahue TR; Hines OJ
    World J Surg; 2009 Apr; 33(4):710-5. PubMed ID: 19057948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.